Form 4: DENTSPLY SIRONA Director Willie Deese Reports Future Equity Acquisition via RSU Dividends

DENTSPLY SIRONA Inc. Director Willie A. Deese reported the future acquisition of 139.41 shares of common stock on July 11, 2025, representing dividends on restricted stock units.

Summary

• Willie A. Deese, a Director of DENTSPLY SIRONA Inc. (XRAY), is set to acquire 139.41 shares of common stock.
• The transaction is scheduled for July 11, 2025.
• These shares are acquired as dividends on existing restricted stock units (RSUs) and are in the form of additional RSUs.
• The acquisition price is $0, indicating it is an award rather than a purchase.
• The newly acquired RSU dividends are subject to the same vesting terms as the underlying awards and will vest simultaneously with them.
• Each RSU converts to common stock on a 1:1 basis.
• Following this reported transaction, Willie A. Deese will beneficially own 57,367.109 shares of DENTSPLY SIRONA Inc. common stock directly.

Sentiment

Score: 7

Explanation: Slightly positive, as it indicates a director's increased stake and alignment with shareholder interests through a routine, non-dilutive (in terms of new shares issued for cash) compensation mechanism.

Positives

• The future acquisition of additional shares by a director, even through RSU dividends, increases their beneficial ownership and aligns their interests further with shareholders.
• The mechanism of RSU dividends indicates a standard compensation practice that rewards long-term holding and performance.

Negatives

• No direct negatives are apparent from this routine, future-dated transaction.

Risks

• The value of the acquired shares is subject to the future performance of DENTSPLY SIRONA Inc.'s stock price.
• The shares are restricted stock units and are subject to vesting terms, meaning they are not immediately liquid or fully owned until those terms are met.

Future Outlook

The acquired restricted stock units are subject to future vesting terms, and the dividends will vest simultaneously with the underlying RSUs, indicating a future conversion to common stock upon meeting these conditions.

Management Comments

• Represents dividends on restricted stock units (RSUs) awarded to the reporting person in the form of additional RSUs and are subject to the same vesting terms as the underlying awards.
• The dividends vest simultaneously with the RSUs to which they relate.
• Each RSU converts to common stock on a 1:1 basis.

Industry Context

The practice of awarding restricted stock units (RSUs) and providing dividends on these units in the form of additional RSUs is a common executive and director compensation strategy across various industries, including healthcare and dental technology, aiming to align long-term interests between management and shareholders.

Comparison to Industry Standards

• This type of RSU dividend acquisition is a standard component of executive and director compensation packages, comparable to practices at other publicly traded companies in the medical device and healthcare sectors, such as Align Technology (ALGN) or Zimmer Biomet (ZBH), which often use equity awards to incentivize long-term performance and retention.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders due to higher beneficial ownership.
• Management/Employees: Reinforces the company's equity compensation structure for directors.

Next Steps

• Continued vesting of the underlying restricted stock units and the newly acquired RSU dividends.
• Future conversion of vested RSUs to common stock.

Key Dates

Keywords

DENTSPLY SIRONA, XRAY, SEC Form 4, Insider Transaction, Director Stock Acquisition, Restricted Stock Units, RSU Dividends, Beneficial Ownership, Corporate Governance, Executive Compensation